Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Raquel Izumi
Ibrutinib as Initial Therapy for Elderly Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b/2 Trial
The Lancet Oncology
Oncology
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
British Journal of Haematology
Hematology
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma Skin Infiltration Triggered by Borrelia Burgdorferi Infection
Revista Romana de Medicina de Laborator
Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukaemia (CLL) and Thrombocytopenia
British Journal of Haematology
Hematology
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Cytometry Part B - Clinical Cytometry
Forensic Medicine
Pathology
Histology
Cell Biology
Chronic Lymphocytic Leukaemia
Nature Reviews Disease Primers
Medicine
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
